- Trials with a EudraCT protocol (40)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
40 result(s) found for: Spontaneous remission.
Displaying page 1 of 2.
EudraCT Number: 2015-003636-13 | Sponsor Protocol Number: CQGE031C2201E1 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQG... | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011137-26 | Sponsor Protocol Number: P06129 | Start Date*: 2009-10-05 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation | |||||||||||||
Full Title: An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-naïve subjects with rheumatoid arthritis ... | |||||||||||||
Medical condition: Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FI (Completed) NL (Completed) HU (Completed) AT (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed) BE (Completed) GR (Completed) DK (Completed) SK (Completed) PT (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004359-35 | Sponsor Protocol Number: ICEA2020.1 | Start Date*: 2020-10-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Induction of Cure in Early Arthritis | |||||||||||||
Medical condition: early unclassified arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004961-42 | Sponsor Protocol Number: BC-6226 | Start Date*: 2020-08-06 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic profiling | |||||||||||||
Medical condition: peripheral spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004077-29 | Sponsor Protocol Number: 2004112 | Start Date*: 2005-02-04 |
Sponsor Name:Procter & Gamble Pharmaceuticals | ||
Full Title: A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day pl... | ||
Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) LT (Completed) SK (Completed) CZ (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003505-26 | Sponsor Protocol Number: TOHNER/31 | Start Date*: 2019-03-18 | |||||||||||
Sponsor Name:ABIOGEN PHARMA S.P.A. | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of treatment with Neridronate 100 mg (4 infusions over a period of 10 days) in patients with tra... | |||||||||||||
Medical condition: Transient osteoporosis of the hip. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000242-38 | Sponsor Protocol Number: BEL114674 | Start Date*: 2013-01-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy | |||||||||||||
Medical condition: Idiopathic Membranous Nephropathy (IMN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005602-31 | Sponsor Protocol Number: mec 06/239 | Start Date*: 2006-10-24 |
Sponsor Name:Academic Medical Center | ||
Full Title: Excimer laser versus clobetason propionaat in prurigo form of atopic dermatitis | ||
Medical condition: the excimer laser appears to be a promising treatment for localized atopic dermatitis. Therefore we designed a randomized trial to investigate the efficacy of this excimer laser versus topical clob... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003123-57 | Sponsor Protocol Number: I6T-MC-AMAC | Start Date*: 2016-02-09 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) HU (Completed) NL (Completed) LT (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005081-34 | Sponsor Protocol Number: JAK-SPARE1 | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing ... | ||
Medical condition: Polymyalgia rheumatica (PMR) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000385-38 | Sponsor Protocol Number: BEL116472 | Start Date*: 2012-05-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy | |||||||||||||
Medical condition: Idiopathic Membranous Glomerulonephropathy (IMGN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002784-91 | Sponsor Protocol Number: HAW0501 | Start Date*: 2006-02-06 |
Sponsor Name:Cardiff and Vale NHS Trust | ||
Full Title: A Randomized, Multicentre, Parallel Group Single-Blind Study to Assess the Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily versus Divided Doses Three Times Dai... | ||
Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002795-13 | Sponsor Protocol Number: RG_12-129 | Start Date*: 2012-12-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A phase II trial of Cyclosporin A in Early Adverse Risk CLL | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001974-28 | Sponsor Protocol Number: 767905/008 | Start Date*: 2005-11-15 |
Sponsor Name:GlaxoSmithKline R&D Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfu... | ||
Medical condition: Opioid-Induced Bowel Dysfunction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) FI (Completed) CZ (Completed) IE (Completed) GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001514-15 | Sponsor Protocol Number: EARLY_KUM_PSY | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:Bezirkskliniken Schwaben | |||||||||||||
Full Title: Effects of early clozapine treatment on remission rates in acute schizophrenia (EARLY) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001171-23 | Sponsor Protocol Number: ON/2016/6004 | Start Date*: 2017-06-26 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate. | ||
Medical condition: Immune Thrombocytopenia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2016-004216-36 | Sponsor Protocol Number: BDPCC | Start Date*: 2017-03-09 | |||||||||||
Sponsor Name:I.R.C.C.S. POLICLINICO SAN DONATO | |||||||||||||
Full Title: Pilot, open-label, spontaneous, Phase II study on the efficacy of beclomethasone dipropionate (BDP) for treatment of Collagenous colitis (CC) | |||||||||||||
Medical condition: collagenous colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001014-17 | Sponsor Protocol Number: RETIC/03/06 | Start Date*: 2007-07-26 | |||||||||||
Sponsor Name:Alfa Wassermann S.p.A. | |||||||||||||
Full Title: A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active... | |||||||||||||
Medical condition: Treatment of moderate, active Crohn’s disease: induction of remission. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003532-32 | Sponsor Protocol Number: LX1606.1-204-UC | Start Date*: 2011-12-19 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Prelimi... | |||||||||||||
Medical condition: Acute mild to moderate ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003090-34 | Sponsor Protocol Number: 1368-0008 | Start Date*: 2019-02-05 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease | |||||||||||||
Medical condition: Fistulizing Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) DE (Completed) NL (Prematurely Ended) HU (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
